Clinical and bacteriological efficacy of sequential intravenous to oral moxifloxacin in hospitalised patients with community-acquired pneumonia due to Enterobacteriaceae
Abstract number: 1733_1518
Choudhri S., Arvis P., Haverstock D.
Objectives: Although S. pneumoniae is the most common bacterial cause of community-acquired pneumonia (CAP), Enterobacteriaceae are an important cause of CAP in patients with underlying comorbid illnesses such as chronic obstructive pulmonary disease. We used pooled data from 6 CAP trials to compare the clinical and microbiological efficacy of sequential intravenous (IV)/oral (PO) moxifloxacin (MXF) with comparator (COMP) therapy in patients with CAP due to Enterobacteriaceae.
Methods: Data were pooled from 6 sequential (IV/PO) trials of 400 mg IV/PO MXF in the treatment of mild, moderate and severe CAP in hospitalised patients. COMP treatment consisted of ceftriaxone + erythromycin, amoxicillin/clavulanate ± clarithromycin, trovafloxacin, levofloxacin, ceftriaxone ± azithromycin ± metronidazole or ceftriaxone + levofloxacin.
Results: The 6 trials randomised 3015 patients (1494 MXF, 1521 COMP) of which 2288 were valid per protocol (PP) (1141 MXF, 1147 COMP). Of the valid PP patients, 342 (30.0%) MXF and 361 (31.5%) COMP-treated subjects were also microbiologically valid. Of these 27 (7.9%) MXF and 15 (4.2%) COMP-treated subjects had Enterobacteriaceae isolated from sputum or blood cultures. The following individual organisms were isolated (MXF, COMP): E. coli (3, 6), Klebsiella spp. (19, 8), Proteus mirabilis (1, 0), Proteus vulgaris (1, 0), Serratia marcescens (0, 1) and Enterobacter cloacae (3, 0). The overall clinical and bacteriological success rates in these patients were 22/27 (81.5%) and 21/27 (77.8%) for MXF and 10/15 (67.0%) and 10/15 (67.0%) for COMP-treated patients.
Conclusions: Sequential therapy with IV/PO moxifloxacin was highly effective in the treatment of CAP due to Enterobacteriaceae.
Research funding: Bayer Health Care Pharmaceuticals.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|